• Cowen & Co. maintains a "Buy" grade for AstraZeneca PLC (NASDAQ:AZN), with a raised price target from $95 to $105.
• JPMorgan names AstraZeneca as its top UK healthcare pick for 2026, highlighting the company's strong pipeline of catalysts.
• AstraZeneca's market capitalization stands at approximately $283 billion, with a trading volume of 7,055,475 shares.

AstraZeneca PLC, trading under the symbol AZN on the NASDAQ, is a prominent player in the global pharmaceutical industry. Known for its innovative drug development, AstraZeneca competes with other major companies like GSK and Novartis. On December 9, 2025, Cowen & Co. maintained its "Buy" grade for AstraZeneca, with the stock priced at $91.28. TD Cowen also raised its price target from $95 to $105, as highlighted by TheFly.

JPMorgan has identified AstraZeneca as its top UK healthcare pick for 2026, emphasizing the company's strong pipeline of catalysts. This recognition comes as investor focus shifts from US drug pricing concerns to innovation. AstraZeneca's stock, currently priced at $91.28, has seen a 1.22% increase today, translating to a rise of $1.10. The stock has fluctuated between $89.67 and $91.365 during the trading day.

AstraZeneca's market capitalization is approximately $283 billion, with a trading volume of 7,055,475 shares. Over the past year, the stock has reached a high of $94.015 and a low of $61.24. In contrast, GSK is positioned lower in JPMorgan's rankings due to a muted growth outlook through 2030 and overly optimistic consensus forecasts. With few significant trial results expected, JPMorgan sees limited potential for a re-rating of GSK.

Novartis, another competitor, is noted as a potential top performer. Its rich pipeline has earned it an upgrade to 'Overweight' by JPMorgan. Despite the competition, AstraZeneca's robust pipeline and strategic focus on innovation position it well for future growth. As investor sentiment shifts, AstraZeneca remains a strong contender in the pharmaceutical sector.